A phase 2B study of CX-1739 in patients with central sleep apnea

Trial Profile

A phase 2B study of CX-1739 in patients with central sleep apnea

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs CX 1739 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Sep 2016 According to a RespireRx Pharmaceuticals media release, final results are expected to be published in the fourth quarter of 2016.
    • 08 Sep 2016 Status changed from recruiting to active, no longer recruiting, as reported in a RespireRx Pharmaceuticals media release.
    • 29 Mar 2016 According to RespireRx media release, data expected in the third quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top